Advertisement
"We are pleased to have Dr. Libby speak about the importance ofinflammation in atherosclerosis," said Lawrence K. Cohen, Ph.D., chiefexecutive officer of VIA Pharmaceuticals. "While there are a number ofcurrently available therapies that help reduce risk factors of heart disease,they do not address inflammation, an underlying cause of atherosclerosis andcomplications such as heart attack and stroke."
Advertisement
Dr. Libby is the Chief of Cardiovascular Medicine at the Brigham andWomen's Hospital in Boston, Massachusetts and serves as the MallinckrodtProfessor of Medicine at Harvard Medical School. He also directs the D.W.Reynolds Cardiovascular Clinical Research Center at Harvard. His current majorresearch focus is the role of inflammation in vascular diseases such asatherosclerosis. Dr. Libby has received numerous awards and recognitions forhis research accomplishments. His areas of clinical expertise include generaland preventive cardiology. Dr. Libby writes a cardiovascular blog,"Consults-Experts on the Front Lines of Medicine", for the New York Timeswebsite (http://consults.blogs.nytimes.com). He is also the co-founder of anon-profit organization called The International Partnership for CriticalMarkers of Disease to promote the development, evaluation, and appropriateclinical utilization of biomarkers. Dr. Libby earned his medical degree at theUniversity of California, San Diego, and completed his training in internalmedicine and cardiology at the Peter Bent Brigham Hospital (now Brigham andWomen's Hospital).
Webcast Information
A live audiovisual webcast of the presentation can be accessed from theinvestor section of the VIA website, http://www.viapharmaceuticals.combeginning at 12:00pm EDT on Tuesday, September 16. The webcast will bearchived for at least 14 days following the presentation.
About VIA Pharmaceuticals, Inc.
VIA Pharmaceuticals, Inc. is a biotechnology company focused on thedevelopment of compounds for the treatment of cardiovascular disease. VIA isbuilding a pipeline of small-molecule drugs that target a significant unmetmedical need: reducing inflammation in the blood vessel wall, which is anunderlying cause of atherosclerosis and its complications, including heartattack and stroke. The company's lead drug candidate, VIA-2291, is in multiple
Phase 2 clinical studies in patients with cardiovascular disease. For moreinformation, visit: http://www.viapharmaceuticals.com.
Forward-Looking Statements
This press release may contain "forward-looking" statements within themeaning of the Private Securities Litigation Reform Act of 1995. Thesestatements relate to future events or to VIA's future financial performanceand involve known and unknown risks, uncertainties and other factors that maycause VIA's actual results, levels of activity, performance or achievements tobe materially different from any future results, levels of activity,performance or achievements expressed or implied by these forward-lookingstatements. In some cases, you can identify forward-looking statements by theuse of words such as "may," "could," "expect," "intend," "plan," "seek,""anticipate," "believe," "estimate," "predict," "potential," "continue" or thenegative
